EGFR and non-small cell lung carcinoma: In recent years, tremendous advances in immune checkpoint inhibitors (ICIs) have significantly improved the overall survival of advanced NSCLC patients without driver mutations, while the efficacy of programmed death 1 (PD-1) axis inhibition in EGFR-positive patients is still controversial.